Half Year Report & Accounts
Released
Released
Announcement PDF
Resonance Health Limited
Appendix 4D
Half-year report
1. Company details
Name of entity: Resonance Health Limited
ABN: 96 006 762 492
Reporting period: For the half-year ended 31 December 2025
Previous period: For the half-year ended 31 December 2024
2. Results for announcement to the market
$
Revenues from ordinary activities up 53% to 7,975,096
Profit from ordinary activities after tax attributable to the owners of
Resonance Health Limited up 241% to 1,466,049
Profit for the half-year attributable to the owners of Resonance Health
Limited up 241% to 1,466,049
Dividends
There were no dividends paid, recommended or declared during the current financial period.
Comments
The profit for the Group after providing for income tax amounted to $1,466,049 (31 December 2024: $1,036,192 loss).
The FY26 half year result included an income tax benefit of $561,343 which was the net difference between the Group’s
Research and Development (R&D) tax incentive refund for R&D performed in the FY2025 year totaling $817,608 and the
total amount of income taxation payable by the Group given its HY2026 financial performance totaling $256,265.
3. Net tangible assets
31 December
2025
30 June
2025
Cents Cents
Net current tangible assets per ordinary security 0.64 0.31
Net tangible assets per ordinary security 0.06 (0.22)
4. Control gained over entities
Not applicable.
5. Loss of control over entities
Not applicable.
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current financial period.
Resonance Health Limited
Appendix 4D
Half-year report
Previous period
There were no dividends paid, recommended or declared during the previous financial period.
7. Audit qualification or review
Details of audit/review dispute or qualification (if any):
The financial statements were subject to a review by the auditors and the review report is attached as part of the Half-
Year Financial Report.
8. Attachments
Details of attachments (if any):
The Half-Year Financial Report of Resonance Health Limited for the half-year ended 31 December 2025 is attached.
9. Signed
Signed ___________________________ Date: 26 February 2026
Mr. Aaron Brinkworth
Chairperson
Perth, Western Australia
Resonance Health Limited
ABN 96 006 762 492
Half-Year Financial Report - 31 December 2025
Resonance Health Limited
Corporate directory
31 December 2025
1
Directors Mr Andrew Harrison – Managing Director
Mr Aaron Brinkworth - Non-executive Chairperson
Mr Mitchell Wells - Non-executive Director
Mr Simon Panton - Non-executive Director
Dr Travis Baroni - Non-executive Director
Company secretary Mr Mitchell Wells
Registered office 141 Burswood Road
BURSWOOD WA 6100
T: +61 8 9286 5300
F: +61 8 9286 5399
Principal place of business 141 Burswood Road
BURSWOOD WA 6100
T: +61 8 9286 5300
F: +61 8 9286 5399
Share register Automic Group
Level 5, 191 St Georges Terrace
Perth WA 6000
Telephone: 1300 288 664
Auditor HLB Mann Judd
Level 4
130 Stirling Street
Perth WA 6000
Solicitors Steinepreis Paganin
Level 14, QV1
250 St Georges Terrace
Perth WA 6000
Bankers National Australia Bank Limited
Stock exchange listing Resonance Health Limited shares are listed on the Australian Securities Exchange
(ASX code: RHT)
Website www.resonancehealth.com
www.trialswest.com.au
email: info@resonancehealth.com
Resonance Health Limited
Contents
31 December 2025
2
Directors' report 3
Auditor's independence declaration 5
Condensed consolidated statement of profit or loss and other comprehensive income 6
Condensed consolidated statement of financial position 7
Condensed consolidated statement of changes in equity 8
Condensed consolidated statement of cash flows 9
Notes to the condensed financial statements 10
Directors' declaration 21
Independent auditor's review report 22
Resonance Health Limited
Directors' report
31 December 2025
3
The Directors present their report, together with the financial statements, on the consolidated entity (referred to
hereafter as the 'Group') consisting of Resonance Health Limited (referred to hereafter as the 'Company' or 'parent entity')
and the entities it controlled at the end of, or during, the half-year ended 31 December 2025.
Directors
The following persons were Directors of Resonance Health Limited during the whole of the financial half-year and up to
the date of this report, unless otherwise stated:
Mr Andrew Harrison (Appointed Managing Director 1 October 2025, previously CEO)
Dr Martin Blake (Resigned 13 November 2025)
Mr Mitchell Wells
Mr Aaron Brinkworth
Mr Simon Panton
Dr Travis Baroni
Principal activities
The Group’s core business is the development and commercialisation of software-as-medical-device (‘SaMD’)
technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled
environment.
The Group’s core SaMD product is FerriScan®, a non-invasive liver analysis technology used for the assessment of iron in
the liver. Other Company SaMDs include Cardiac T2*, for the assessment of iron in the heart, and HepaFat-Scan® for the
assessment of fat in and around the liver. The Company also has several AI-assisted SaMDs including FerriSmart®,
HepaFatSmart, and LiverSmart®.
In addition to its core business, the Group operates as the Clinical Trial Research Organisation (CRO) and local sponsor in
Australia on clinical trials for a major global pharmaceutical company’s new drug compound. As at the date of this report,
the Group is currently acting as CRO on one clinical trial for this customer with another clinical trial for this customer
having recently been completed. The Group is overseeing aspects of the conduct and delivery of this trial in Australia.
The Group further expanded into the clinical trial ecosystem during the FY2024 financial year with the acquisition of
TrialsWest Pty Ltd (TrialsWest). TrialsWest is a clinical research centre that partners with some of the world’s leading
pharmaceutical and biotechnology companies to help bring new medicines and vaccines to the global community.
Specifically, TrialsWest offers site management services to the clinical trial market specializing in the delivery of clinical
trials in the community.
Review of operations
The profit for the Group after providing for income tax amounted to $1,466,049 (31 December 2024: $1,036,192 loss).
The FY2026 half year result included an income tax benefit of $561,343 which was the net difference between the Group’s
Research and Development (R&D) tax incentive refund for R&D performed in the FY2025 year totaling $817,608 and the
total amount of income taxation payable by the Group given its HY2026 financial performance totaling $256,265.
Sales revenue increased by 53% to $7,975,096 (31 December 2024: $5,210,477), and Revenue and Other Income increased
by 52% to $7,984,214 (31 December 2024: $5,268,641). The higher revenues were driven by the continuation of the
clinical trial agreements with a global pharmaceutical company which contributed approximately $4.4 million in revenue
in the period and the further integration of TrialsWest into the Group which contributed approximately $1.8 million in
revenue in the period (31 December 2024: $1.5 million). In addition, the Group experienced increased sales volumes
across its Ferriscan and HepaFatSmart products in particular and recently introduced two new clinical use only SaMD
products including Magnetic Resonance Elastography (MRE) used to analyse liver stiffness as well as a Visceral and
Subcutaneous Fat measurement.
The revenue associated with the delivery of the clinical trial agreements with a global pharmaceutical company is
recognised according to the delivery of the trials rather than amounts invoiced. Total invoiced amounts in the half year
period related to these two clinical trials was $2.7 million (compared to revenue recognised of $4.4 million).
Resonance Health Limited
Directors' report
31 December 2025
4
Research and development expenditure totalled $601,617 for the half-year (31 December 2024: $870,112). This
comprised capitalised development costs of $103,106 that are recognised as an intangible asset on the Condensed
Statement of Financial Position and items recognised in the Condensed Statement of Comprehensive Income, being
$249,858 amortisation expense and $248,653 research and development expense.
Intangible assets, representing capitalised research and development expenditure, goodwill and other intangible assets,
totalled $9,392,959 at the end of the half-year (30 June 2025: $9,539,711).
The Group has $2,690,957 in cash and cash equivalents at the end of the half-year (30 June 2025: $2,976,570).
Significant changes in the state of affairs
There were no other significant changes in the state of affairs of the Group during the financial half-year.
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out
immediately after this Directors' report.
This report is made in accordance with a resolution of Directors, pursuant to section 306(3)(a) of the Corporations Act
2001.
On behalf of the Directors
___________________________
Mr. Aaron Brinkworth
Chairperson
26 February 2026
Perth, Western Australia
5
AUDITOR’S INDEPENDENCE DECLARATION
As lead auditor for the review of the consolidated financial report of Resonance Health Limited for
the half-year ended 31 December 2025, I declare that to the best of my knowledge and belief, there
have been no contraventions of:
a) the auditor independence requirements of the Corporations Act 2001 in relation to the review;
and
b) any applicable code of professional conduct in relation to the review.
Perth, Western Australia
26 February 2026
N G Neill
Partner
Resonance Health Limited
Condensed consolidated statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2025
Consolidated
Note 31 Dec 2025 31 Dec 2024
$ $
The above condensed statement of profit or loss and other comprehensive income should be read in conjunction with the
accompanying notes
6
Revenue 4 7,975,096 5,210,477
Other income 5 9,118 58,164
Expenses
Depreciation expense 7,8 (228,275) (215,417)
Amortisation expense 9 (249,858) (273,990)
Share-based payments (82,716) (142,490)
Marketing & travel (95,930) (455,663)
Consulting and professional services (1,901,167) (1,440,359)
Employee benefits expense (3,223,593) (2,815,433)
Research and development (248,653) (512,403)
Statutory and compliance (134,886) (174,269)
Foreign exchange gain/(loss) (39,391) 66,228
Finance costs (171,692) (155,615)
Occupancy expenses (106,156) (169,094)
Other expenses (597,191) (489,614)
Profit/(Loss) before income tax benefit 904,706 (1,509,478)
Income tax benefit 6 561,343 473,286
Profit/(Loss) after income tax benefit for the half-year attributable to the owners
of Resonance Health Limited 1,466,049 (1,036,192)
Other comprehensive income for the half-year, net of tax - -
Total comprehensive profit/(loss) for the half-year attributable to the owners of
Resonance Health Limited 1,466,049 (1,036,192)
Cents Cents
Basic profit/(loss) per share 0.31 (0.23)
Diluted profit/(loss) per share 0.30 (0.23)
Resonance Health Limited
Condensed consolidated statement of financial position
As at 31 December 2025
Consolidated
Note 31 Dec 2025 30 Jun 2025
$ $
The above condensed statement of financial position should be read in conjunction with the accompanying notes
7
Assets
Current assets
Cash and cash equivalents 2,690,957 2,976,570
Trade and other receivables 3,540,564 3,518,940
Other assets 298,922 119,234
Total current assets 6,530,443 6,614,744
Non-current assets
Property, plant and equipment 7 634,209 692,006
Right-of-use assets 8 1,274,883 881,370
Intangibles 9 9,392,959 9,539,711
Other assets 130,211 161,816
Total non-current assets 11,432,262 11,274,903
Total assets 17,962,705 17,889,647
Liabilities
Current liabilities
Trade and other payables 1,569,732 1,266,082
Lease liabilities 10 207,863 167,921
Provisions 428,342 149,454
Borrowings 320,000 320,000
Other liabilities 11 890,023 3,195,490
Deferred Consideration Payable 85,163 85,163
Total current liabilities 3,501,123 5,184,110
Non-current liabilities
Lease liabilities 10 1,148,686 781,406
Borrowings 2,373,334 2,533,334
Total non-current liabilities 3,522,020 3,314,740
Total liabilities 7,023,143 8,498,850
Net assets 10,939,562 9,390,797
Equity
Issued capital 12 74,667,429 74,452,640
Reserves (177,365) 2,543,495
Accumulated losses (63,550,502) (67,605,338)
Total equity 10,939,562 9,390,797
Resonance Health Limited
Condensed consolidated statement of changes in equity
For the half-year ended 31 December 2025
The above condensed statement of changes in equity should be read in conjunction with the accompanying notes
8
Issued
Foreign
currency
translation Options Accumulated
Total equity
capital reserve reserve losses
Consolidated $ $ $ $ $
Balance at 1 July 2024 74,166,888 (270,580) 2,907,725 (65,872,400) 10,931,633
Loss after income tax benefit for the half-year - - - (1,036,192) (1,036,192)
Other comprehensive income for the half-
year, net of tax - - - - -
Total comprehensive loss for the half-year - - - (1,036,192) (1,036,192)
Transactions with owners in their capacity as
owners:
Vesting of Tranche A Performance Rights 285,752 - (285,752) - -
Share-based payments - - 142,490 - 142,490
Balance at 31 December 2024 74,452,640 (270,580) 2,764,463 (66,908,592) 10,037,931
Issued
Foreign
currency
translation Options Accumulated
Total equity
capital reserve reserve losses
Consolidated $ $ $ $ $
Balance at 1 July 2025 74,452,640 (270,580) 2,814,075 (67,605,338) 9,390,797
Profit after income tax benefit for the half-
year - - - 1,466,049 1,466,049
Other comprehensive income for the half-
year, net of tax - - - - -
Total comprehensive profit for the half-year - - - 1,466,049 1,466,049
Transactions with owners in their capacity as
owners:
Vesting of Tranche C Performance Rights
(note 17) 214,789 - (214,789) - -
Share-based payments (note 17) - - 82,716 - 82,716
Transfer for lapsed PRs - - (2,588,787) 2,588,787 -
Balance at 31 December 2025 74,667,429 (270,580) 93,215 (63,550,502) 10,939,562
Resonance Health Limited
Condensed consolidated statement of cash flows
For the half-year ended 31 December 2025
Consolidated
Note 31 Dec 2025 31 Dec 2024
$ $
The above condensed statement of cash flows should be read in conjunction with the accompanying notes
9
Cash flows from operating activities
Receipts from customers 5,945,024 8,287,630
Payments to suppliers and employees (5,677,508) (7,213,227)
267,516 1,074,403
Interest received 9,118 33,605
Grants received - 25,500
Interest and other Finance Costs Paid (103,275) (124,837)
Income Taxes Paid - (7,353)
Net cash provided by operating activities 173,359 1,001,318
Cash flows from investing activities
Cash paid to acquire TrialsWest (deferred consideration) - (3,914,836)
Payments for property, plant and equipment (36,462) (105,935)
Payments for intangibles 9 (103,106) (83,719)
Net cash used in investing activities (139,568) (4,104,490)
Cash flows from financing activities
Repayment of lease liabilities (151,616) (133,659)
Repayment of borrowings (160,000) (160,000)
Payments for cash-backed guarantees 31,603 (11,502)
Net cash used in financing activities (280,013) (305,161)
Net decrease in cash and cash equivalents (246,222) (3,408,333)
Cash and cash equivalents at the beginning of the financial half-year 2,976,570 6,854,820
Effects of exchange rate changes on cash and cash equivalents (39,391) 66,228
Cash and cash equivalents at the end of the financial half-year 2,690,957 3,512,715
Resonance Health Limited
Notes to the condensed financial statements
31 December 2025
10
Note 1. General information
The financial statements cover Resonance Health Limited as a Group consisting of Resonance Health Limited and the
entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars,
which is Resonance Health Limited's functional and presentation currency.
Resonance Health Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its
registered office and principal place of business is:
141 Burswood Road
BURSWOOD WA 6100
T: +61 8 9286 5300
F: +61 8 9286 5399
A description of the nature of the Group's operations and its principal activities is included in the Directors' report, which
is not part of the financial statements.
The financial statements were authorised for issue, in accordance with a resolution of Directors, on 26 February 2026.
Note 2. Significant accounting policies
These general-purpose financial statements for the interim half-year reporting period ended 31 December 2025 have
been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the
Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with
International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.
These general-purpose financial statements do not include all the notes of the type normally included in annual financial
statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year
ended 30 June 2025 and any public announcements made by the Company during the interim reporting period in
accordance with the continuous disclosure requirements of the Corporations Act 2001.
The principal accounting policies adopted are consistent with those of the previous financial year and corresponding
interim reporting period, unless otherwise stated.
New or amended Accounting Standards and Interpretations adopted
The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian
Accounting Standards Board ('AASB') that are mandatory for the current reporting period. These had no material impact
on the group.
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.
These are not likely to have material effect on the group.
Going concern
The financial report has been prepared on the going concern basis, which contemplates continuity of normal business
activities and the realisation of assets and settlement of liabilities in the ordinary course of business.
Note 3. Operating segments
Identification of reportable operating segments
The chief operating decision maker is considered to be the Company’s Board of Directors. The Group’s operating segments
are determined by differences in the type of activities performed. The financial results of the Group’s operating segments
are reviewed by the Board of Directors on a monthly basis.
Resonance Health Limited
Notes to the condensed financial statements
31 December 2025
Note 3. Operating segments (continued)
11
Business Segments
The following table presents revenue and profit/(loss) information and certain asset and liability information regarding
business segments for the half-year ended 31 December 2025.
SaMD1
Corporate
Resonance
Clinical TrialsWest Total
Consolidated - 31 Dec 2025 $ $ $ $ $
Revenue
Sales to external customers 3,294,337 - 4,380,195 1,826,042 9,500,574
Total segment revenue 3,294,337 - 4,380,195 1,826,042 9,500,574
Reconciliation of segment revenue to
Group revenue:
- Intersegment elimination (1,525,478)
Total Group Revenue 7,975,096
Total revenue 3,294,337 - 4,380,195 1,826,042 9,500,574
Other income - 9,118 - - 9,118
Other expenses (1,782,903) (2,226,104) (3,158,771) (1,437,208) (8,604,986)
(Loss)/profit before income tax
benefit 1,511,434 (2,216,986) 1,221,424 388,834 904,706
Income tax benefit 561,343
Loss after income tax benefit 1,466,049
Assets
Segment assets 3,971,598 6,243,320 688,750 7,059,037 17,962,705
Total assets 3,971,598 6,243,320 688,750 7,059,037 17,962,705
Liabilities
Segment liabilities 1,471,264 2,034,189 2,092,568 1,425,122 7,023,143
Total liabilities 1,471,264 2,034,189 2,092,568 1,425,122 7,023,143
1. The previously disclosed R&D segment has now been included within the SaMD segment, to reflect current management
reporting and align cashflows with the assets that generate them.
Resonance Health Limited
Notes to the condensed financial statements
31 December 2025
Note 3. Operating segments (continued)
12
SaMD1
Corporate CRO TrialsWest Total
Consolidated - 31 Dec 2024 $ $ $ $ $
Revenue
Sales to external customers 2,562,864 - 1,718,212 1,526,372 5,807,448
Total segment revenue 2,562,864 - 1,718,212 1,526,372 5,807,448
Reconciliation of segment revenue to
Group revenue:
- Intersegment elimination (596,971)
Total Group Revenue 5,210,477
Total revenue 2,562,864 - 1,718,212 1,526,372 5,807,448
Other income - 58,164 - - 58,164
Other expenses (2,224,398) (1,996,085) (2,075,264) (1,079,343) (7,375,090)
(Loss)/profit before income tax
benefit 338,466 (1,937,921) (357,052) 447,029 (1,509,478)
Income tax benefit 473,286
Loss after income tax benefit (1,036,192)
Assets
Segment assets 3,621,897 5,866,742 690,444 7,759,259 17,938,342
Total assets 3,621,897 5,866,742 690,444 7,759,259 17,938,342
Liabilities
Segment liabilities 1,376,702 3,343,528 2,515,428 664,753 7,900,411
Total liabilities 1,376,702 3,343,528 2,515,428 664,753 7,900,411
1. The previously disclosed R&D segment has now been included within the SaMD segment, to reflect current management
reporting and align cashflows with the assets that generate them.
The Group derived 55% of its external customer sales revenue from one major customer. For the period to
December 2024, the Group derived 32% of its external customer sales revenue from one major customer.
Geographical Segments
The Group earns revenue in three significant geographical regions, countries are grouped in the regions of Asia/Pacific,
North America and Europe-Middle East-Africa (EMEA).
All non-current assets are located in Australia being the Asia/Pacific region, applicable disclosure information is disclosed
in Business Segment assets and no additional disclosure is made.
Consolidated
31 Dec 2025 31 Dec 2024
$ $
Asia/Pacific 5,514,764 2,872,246
North America 1,549,318 1,416,078
EMEA 911,014 922,153
Total sales to external customers 7,975,096 5,210,477
Resonance Health Limited
Notes to the condensed financial statements
31 December 2025
13
Note 4. Revenue
Disaggregation of revenue
The Group derives its revenue from the services at a point in time and over time in the following major categories. This is
consistent with the revenue information that is disclosed for each reportable segment:
Consolidated
31 Dec 2025 31 Dec 2024
$ $
Revenue from contracts with customers
At a point in time:
Commercial revenue 1,625,702 1,574,238
Clinical trials 1,042,310 1,278,182
Other studies 216,755 226,486
Over time:
Clinical trials 5,090,329 2,131,571
Revenue 7,975,096 5,210,477
Reconciliation of revenue from contracts with customers with the amounts disclosed in segment information
Consolidated
31 Dec 2025 31 Dec 2024
$ $
Segment revenue 7,975,096 5,210,477
Adjustments and eliminations - -
Total revenue from contracts with customers 7,975,096 5,210,477
Note 5. Other income
Consolidated
31 Dec 2025 31 Dec 2024
$ $
Subsidies and grants - 25,500
Interest revenue 9,118 32,664
Other income 9,118 58,164
Note 6. Income Tax Benefit
Consolidated
31 Dec 2025 31 Dec 2024
$ $
Research and Development tax offset 817,608 786,417
Tax paid (256,265) (313,131)
Aggregate income tax benefit 561,343 473,286
Resonance Health Limited
Notes to the condensed financial statements
31 December 2025
14
Note 7. Property, plant and equipment
Consolidated
31 Dec 2025 30 Jun 2025
$ $
Non-current assets
Plant and equipment - at cost 1,152,746 1,115,042
Less: Accumulated depreciation (518,537) (423,036)
634,209 692,006
Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial half-year are set
out below:
Plant and
equipment
Consolidated $
Balance at 1 July 2024 522,791
Additions 444,102
PPE acquired - Acquisition of TrialsWest (2,180)
Disposals (100,062)
Depreciation expense (172,645)
Balance at 30 June 2025 692,006
Additions 37,705
Disposals -
Depreciation expense (95,502)
Balance at 31 December 2025 634,209
Note 8. Right-of-use assets
Consolidated
31 Dec 2025 30 Jun 2025
$ $
Non-current assets
Land and buildings - right-of-use 1,501,111 1,433,660
Less: Accumulated depreciation (226,228) (552,290)
1,274,883 881,370
The Group leases five premises.
Resonance Health Limited
Notes to the condensed financial statements
31 December 2025
Note 8. Right-of-use assets (continued)
15
Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial half-year are set
out below:
Land and
buildings
Consolidated $
Balance at 1 July 2024 492,048
Additions 655,561
Depreciation expense (266,239)
Balance at 30 June 2025 881,370
Additions1
620,214
Depreciation expense (132,773)
Disposal (93,928)
Balance at 31 December 2025 1,274,883
1. Additions comprise of a third site in Mandurah for the TrialsWest business and an extension of an existing lease.
Note 9. Intangibles
Consolidated
31 Dec 2025 30 Jun 2025
$ $
Non-current assets
Development - at cost 4,771,166 4,668,060
Less: Accumulated amortisation (2,233,757) (2,117,878)
Goodwill 5,270,147 5,270,147
Other Intangible Assets 2,007,000 2,007,000
Less: Accumulated amortisation (421,597) (287,618)
9,392,959 9,539,711
Resonance Health Limited
Notes to the condensed financial statements
31 December 2025
Note 9. Intangibles (continued)
16
Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial periods are set
out below:
Fibrosis AI &
Automation
Tools
Goodwill Customer
Contracts/
Relationships
Patient
Database
Total
$ $ $ $ $ $
Balance at 1 July 2024 998,011 1,608,173 5,250,606 1,806,000 201,000 9,863,790
Additions 96,938 82,836 - - - 179,774
Goodwill on acquisition of
TrialsWest
- 19,541 - - 19,541
Amortisation expense - (235,776) - (244,138) (43,480) (523,394)
Balance at 30 June 2025 1,094,949 1,455,233 5,270,147 1,561,862 157,520 9,539,711
Additions 76,034 27,072 - - - 103,106
Amortisation expense - (115,879) - (113,725) (20,254) (249,858)
Balance at 31 December 2025 1,170,983 1,366,426 5,270,147 1,448,137 137,266 9,392,959
Development Assets
Development expenditure relates to costs incurred in developing MRI image analysis tools for the diagnosis and clinical
management of human disease.
During the current financial year this development has related primarily to automation of organ fat and iron assessment
tools, further refinement of FerriScan® and the next stage of development of an MRI based liver fibrosis tool.
The recoupment of development expenditure is dependent on the successful development and commercialisation or sale
of the technology developed. The Directors are required to assess at each reporting date whether there is an indication
that an asset may be impaired. If any such indication exists an estimate is made of the asset’s recoverable amount.
Impairment tests are also required for intangible assets not yet ready for use regardless of the existence of indicators of
impairment. Where the asset’s carrying value exceeds the estimated recoverable amount a provision for impairment is
recognised.
In making this assessment the Directors had regard to the size of the liver iron, liver fibrosis and liver fat markets,
competing products, experience gained with the FerriScan® technology, the likely period over which these revenues are
expected to be generated and the likelihood of any technological obsolescence.
Based upon this assessment, no impairment indicators were determined to be present at 31 December 2025. A full
impairment assessment including intangible assets not yet available for use will be conducted at 30 June 2026 in
accordance with AASB 136.
Goodwill and Other Intangible Assets
Goodwill and Other identifiable intangible assets were recognised as a result of the acquisition of TrialsWest Pty Ltd
(TrialsWest) in previous years. These other intangible assets include Customer Contracts/Relationships and a Patient
Database.
Resonance Health Limited
Notes to the condensed financial statements
31 December 2025
Note 9. Intangibles (continued)
17
The recoupment of these assets is dependent on the generation of cashflows from the TrialsWest business going forward.
The directors have assessed that no impairment indicators were determined to be present at 31 December 2025 for these
intangible assets. A full impairment assessment for these goodwill and other intangible assets will be conducted at 30 June
2026 in accordance with AASB 136.
Note 10. Lease liabilities
The Group leases only premises.
Consolidated
31 Dec 2025 30 Jun 2025
$ $
Current liabilities
Lease liability 207,863 167,921
Non-current liabilities
Lease liability 1,148,686 781,406
1,356,549 949,327
Note 11. Other Liabilities
This balance represents amounts received from contracts with customers where the performance obligations for
recognising revenue have yet to be met at balance date.
Consolidated
31 Dec 2025 30 Jun 2025
$ $
Current liabilities
Unearned income 890,023 3,195,490
Note 12. Issued capital
Consolidated
31 Dec 2025 30 Jun 2025 31 Dec 2025 30 Jun 2025
Shares Shares $ $
Ordinary shares - fully paid 474,792,647 459,904,488 74,667,429 74,452,640
On 8 August 2025, 11,145,177 Loan Shares were provided to the CEO and CFO per which they repay the Company $0.0395
for each loan share issued to them, within 5 years from the issue date. Loan shares not repaid by that date will be forfeited.
Refer to note 17 for further details.
On 28 October 2025, 4,031,332 Tranche C Performance Rights vested and were converted into shares. As a result, the fair
value at date of issue was transferred from reserves to issued capital totalling $214,789.
Resonance Health Limited
Notes to the condensed financial statements
31 December 2
Share your feedback
Discover